T
LGND icon

Tidemark’s Ligand Pharmaceuticals LGND Stock Holding History

Tidemark’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4
Closed -$337 – 634
2024
Q2 		$337 Hold
4
– – ﹤0.01% 599
2024
Q1 		$292 Hold
4
– – ﹤0.01% 676
2023
Q4 		$286 Buy
+4
New +$236 ﹤0.01% 672

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

Tidemark's LGND Position: Q3 2024 in Review

Tidemark sold out of Ligand Pharmaceuticals (LGND) in Q3 2024, closing a stake of 4 shares — an estimated $337 sold.

Tidemark first reported a position in LGND in Q4 2023 and held it in 3 quarters. The position peaked at $337 in Q2 2024. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

  • Tidemark reported no remaining Ligand Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Tidemark sold 4 Ligand Pharmaceuticals shares in Q3 2024, an estimated $337.
  • Tidemark first reported a position in Ligand Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Tidemark's Ligand Pharmaceuticals position peaked at $337 in Q2 2024.
  • 243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on Tidemark's 13F filing for Q3 2024, filed 7 Nov 2024.